Controlled release pharmaceutical formulations
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
1. A pharmaceutical composition comprising a plurality of releasable drug moieties, wherein each drug moiety comprises at least one carboxylic acid group and at least one hydroxyl group, wherein at least some drug moieties are covalently attached to each other through said at least one hydroxyl group of one drug moiety and said at least one carboxylic acid group of another drug moiety, thereby forming a polymer, wherein the polymer is at least a trimer and wherein the drug moiety is a prostacyclin.
2. The pharmaceutical composition of claim 1 , wherein the covalent attachment is an ester bond formed between said at least one hydroxyl group and said at least one carboxylic group.
3. The pharmaceutical composition of claim 1 , wherein the prostacyclin compound is selected from the group consisting of epoprostenol, treprostinil, beraprost, iloprost, cicaprost, and prostaglandin I2.
4. The pharmaceutical composition of claim 3 , wherein the prostacyclin compound is treprostinil.
5. The pharmaceutical composition of claim 1 , wherein the prostacyclin compound is a compound of Formula (I)
Wherein
represents a single or a double bond;
Z 1 and Z 2 each independently represents an O or CH 2 ;
p=0 or 1;
m=1, 2, or 3;
R 1 represents a H or an acid protective group;
R 2 and R 3 each independently represents a H or a hydroxyl protective group;
R 4 represents H and the other represents a Ci-6 alkyl; and R 5 represents a C1- 6 alkyl group or C 2-8 alkynylene group.
6. The pharmaceutical composition of claim 1 , further comprising a co-monomer covalently bonded to the carboxylic acid group of one drug moiety and the hydroxyl group of a second drug moiety.
7. The pharmaceutical composition of claim 6 , wherein the polymer is insoluble in water.
8. The pharmaceutical composition of claim 6 , wherein the polymer is soluble in water.
9. The pharmaceutical composition of claim 6 , wherein the co-monomer is selected from the group consisting of 6-hydroxyhexanoic acid, beta-hydroxybutyric acid, hydroxyl-polyethylene glycol-carboxylic acid, lactic acid, and glycolic acid.
10. The pharmaceutical composition of claim 1 , wherein the drug moieties that form the polymer have a structure selected from the group consisting of Formulae (IIa), (IIb), and (IIc):
11. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11 , wherein the composition is in a form suitable for injection.
13. The pharmaceutical composition of claim 12 , wherein the form is suitable for a subcutaneous or intramuscular injection.
14. The pharmaceutical composition of claim 11 , wherein the composition is in a form suitable for implant.
15. A pharmaceutical composition comprising a therapeutically effective amount of a polymer comprising a plurality of releasable drug moieties, wherein each drug moiety comprises at least one carboxylic acid group and at least one hydroxyl group, wherein at least some drug moieties are covalently attached to each other through said at least one hydroxyl group of one drug moiety and said at least one carboxylic acid group of another drug moiety, thereby forming the polymer, wherein the drug moiety is a prostacyclin.
16. The pharmaceutical composition of claim 15 , wherein the polymer is at least a trimer.